Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

BLUMORPHO : revenue, balance sheet and financial ratios

BLUMORPHO is a French company founded 11 years ago, specialized in the sector Activités des sièges sociaux. Based in PARIS (75008), this company of category PME shows in 2024 a net income positive of 5 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BLUMORPHO (SIREN 809387046)
Indicator 2024 2023 2022 2021
Revenue N/C N/C N/C N/C
Net income 4 713 € 7 094 € 83 521 € 47 887 €
EBITDA N/C N/C N/C N/C
Net margin N/C N/C N/C N/C

Revenue and income statement

In 2024, BLUMORPHO generates positive net income of 5 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2024: 48 k€ -> 5 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

4 713 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 19%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.555%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

18.567%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

46.5%

Solvency indicators evolution
BLUMORPHO

Sector positioning

Debt ratio
0.56 2024
2022
2023
2024
Q1: 0.06
Med: 14.64
Q3: 89.5
Good -6 pts over 3 years

In 2024, the debt ratio of BLUMORPHO (0.56) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
18.57% 2024
2022
2023
2024
Q1: 11.6%
Med: 51.97%
Q3: 85.23%
Average

In 2024, the financial autonomy of BLUMORPHO (18.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 125.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

125.467

Liquidity indicators evolution
BLUMORPHO

Sector positioning

Liquidity ratio
125.47 2024
2022
2023
2024
Q1: 116.82
Med: 458.52
Q3: 2178.3
Average

In 2024, the liquidity ratio of BLUMORPHO (125.47) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Positioning of BLUMORPHO in its sector

Comparison with sector Activités des sièges sociaux

Valuation estimate

Based on 103 transactions of similar company sales in 2024, the value of BLUMORPHO is estimated at 44 810 € (range 15 386€ - 120 661€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
103 transactions
15k€ 44k€ 120k€
44 810 € Range: 15 386€ - 120 661€
NAF 5 année 2024

Valuation method used

Net Income Multiple
4 713 € × 9.5x = 44 811 €
Range: 15 386€ - 120 662€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sièges sociaux)

Compare BLUMORPHO with other companies in the same sector:

Frequently asked questions about BLUMORPHO

What is the revenue of BLUMORPHO ?

The revenue of BLUMORPHO is not publicly disclosed (confidential accounts filed with INPI).

Is BLUMORPHO profitable?

Yes, BLUMORPHO generated a net profit of 5 k€ in 2024.

Where is the headquarters of BLUMORPHO ?

The headquarters of BLUMORPHO is located in PARIS (75008), in the department Paris.

Where to find the tax return of BLUMORPHO ?

The tax return of BLUMORPHO is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BLUMORPHO operate?

BLUMORPHO operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.